AbbVie reported a 12.4% year-over-year increase in Q1 net revenues, showing strong business momentum despite some challenges in its Immunology portfolio. The company raised its full-year 2026 EPS guidance, projecting 14% annual underlying EPS growth after adjusting for IPR&D and milestone expenses. AbbVie is also investing strategically, including a $1.4 billion campus in North Carolina, to support long-term innovation and reduce political risks. These factors suggest confidence in AbbVie's fundamentals and valuation near multiyear lows, making it a buy recommendation.
AbbVie is gaining investor confidence as its new immunology drugs Skyrizi and Rinvoq show strong revenue growth, offsetting declines from older products like Humira. The company raised its full-year earnings forecast after beating revenue expectation...
BOTOX Cosmetic, under Allergan Aesthetics and AbbVie, announced 250 women entrepreneurs chosen for The Confidence Collective program, offering skill-building, mentorship, and networking. From this group, 20 participants will receive $20,000 grants to...
Biotech mergers and acquisitions are gaining momentum as Big Pharma seeks to offset upcoming patent losses. Among potential targets, Legend Biotech stands out for its revenue-generating CAR-T therapy Carvykti, co-developed with Johnson & Johnson, sho...
The 16th annual PODD (Partnership Opportunities in Drug Delivery) conference will take place on October 29-30, 2026, in Boston, gathering over 1,000 industry leaders to discuss advancements in drug delivery systems. The event features over 150 sessio...
Canada has approved Boey®, the first rapid-onset and short-duration botulinum neurotoxin serotype E, for temporarily improving moderate to severe glabellar (frown) lines. Developed by Allergan Aesthetics, Boey® offers results visible as early as eigh...
